3.170CHF+0.96%Mkt Cap: 118.91M CHFP/E: —Last update: 2026-06-01
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP03…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap118.91M CHF
Enterprise Value42.50M CHF
Revenue (TTM)—
Gross Profit-39.14M CHF
Net Income (TTM)-61.65M CHF
Revenue/Share—
Last Price3.170 CHF
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees134
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0256379097
Valuation
P/E (Trailing)—
P/E (Forward)13.59
PEG—
EV/EBITDA-0.82
EV/Revenue—
P/S—
P/B1.72
EPS (TTM)-1.58
EPS (Forward)0.23
52W Range
2.66039% of range3.960
52W High3.960 CHF
52W Low2.660 CHF
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.74%
ROA-60.38%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.26M CHF
CapEx (TTM)714.00K CHF
FCF Margin—
FCF Yield-21.01%
Net Debt-75.42M CHF
Net Debt/EBITDA1.45
Balance Sheet
Debt/Equity0.05
Current Ratio9.43
Quick Ratio9.21
Book Value/Sh1.823 CHF
Cash/Share2.097 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.000 CHF
Target Range3.000 CHF – 15.00 CHF
# Analysts2
Ownership
Shares Out.37.51M
Float19.89M
Insiders8.47%
Institutions43.80%
Technical
SMA 503.239 (-2.1%)
SMA 2003.225 (-1.7%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)30.00K
Avg Vol (10d)27.14K
Technical Indicators
RSI (14)49.4
MACD-0.0626
MACD Signal-0.0800
MACD Hist.+0.0174
BB Upper3.439 CHF
BB Middle3.124 CHF
BB Lower2.809 CHF
BB Width20.15%
ATR (14)0.1690 CHF
Vol Ratio (20d)0.48x